Diamyd Medical AB (publ) DMYD.B
Updated: 11 Jun 2026
No signal published yet
We already track Diamyd Medical and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Diamyd Medical AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Diamyd Medical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 11, 2026, Diamyd Medical received a Notice of Allowance for a key precision medicine patent for its insulin-based treatment. This follows the company's April 2026 decision to discontinue its Phase 3 DIAGNODE-3 trial due to lack of efficacy and the subsequent initiation of a strategic review. The company is currently evaluating external proposals and cost-reduction measures to maximize shareholder value.
What Firelda Watch includes for Diamyd Medical AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Diamyd Medical AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Diamyd Medical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more